Semen enhances transmitted/founder HIV-1 infection and only marginally reduces antiviral activity of broadly neutralizing antibodies

被引:0
|
作者
von Maltitz, Pascal [1 ]
Wettstein, Lukas [1 ]
Weil, Tatjana [1 ]
Schommers, Philipp [2 ,3 ,4 ,5 ,6 ,7 ]
Klein, Florian [2 ,3 ,4 ,5 ]
Muench, Jan [1 ]
机构
[1] Univ Ulm Med Ctr, Inst Mol Virol, Ulm, Germany
[2] Univ Cologne, Inst Virol, Fac Med, Lab Expt Immunol, Cologne, Germany
[3] Univ Hosp Cologne, Cologne, Germany
[4] German Ctr Infect Res, Cologne, Germany
[5] Ctr Mol Med Cologne CMMC, Cologne, Germany
[6] Univ Cologne, Fac Med, Dept Internal Med 1, Cologne, Germany
[7] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
关键词
bNAb; HIV-1; semen; microbicide; DOUBLE-BLIND; VAGINAL GEL; PREVENTION; MICROBICIDES; PHASE-3;
D O I
10.1128/jvi.01190-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Topically applied microbicides may play a critical role in preventing sexual transmission of human immunodeficiency virus type 1 (HIV-1); however, their efficacy can be compromised by amyloid fibrils present in semen, which significantly increase HIV-1 infectivity. This phenomenon may have contributed to the failure of most microbicide candidates in clinical settings. Understanding the impact of semen on microbicide effectiveness is thus crucial. In our study, we evaluated the influence of semen on the neutralizing activity of broadly neutralizing antibodies (bNAbs), including PG16, PGT121, 10-1074, 3BNC117, and VRC01, which are potential microbicide candidates. We found that semen enhances infection of HIV-1 transmitted/founder viruses but only marginally affects the neutralizing activity of tested antibodies, suggesting their potential for microbicide application. Our findings underscore the need to consider semen-mediated enhancement when evaluating and developing microbicides and highlight the potential of incorporating HIV-1 bNAbs in formulations to enhance efficacy and mitigate HIV-1 transmission during sexual encounters.IMPORTANCEThis study examined the impact of semen on the development of microbicides, substances used to prevent the transmission of HIV-1 during sexual activity. Semen contains certain components that can render the virus more infectious, posing a challenge to microbicide effectiveness. Researchers specifically investigated the effect of semen on a group of powerful antibodies called broadly neutralizing antibodies, which can neutralize a large spectrum of different HIV-1 variants. The results revealed that semen only had a minimal effect on the antibodies' ability to neutralize the virus. This is promising because it suggests that these antibodies could still be effective in microbicides, even in the presence of semen. Understanding this interaction is crucial for developing better strategies to prevent HIV-1 transmission. By incorporating the knowledge gained from this study, scientists can now focus on creating microbicides that consider the impact of semen, bringing us closer to more effective prevention methods. This study examined the impact of semen on the development of microbicides, substances used to prevent the transmission of HIV-1 during sexual activity. Semen contains certain components that can render the virus more infectious, posing a challenge to microbicide effectiveness. Researchers specifically investigated the effect of semen on a group of powerful antibodies called broadly neutralizing antibodies, which can neutralize a large spectrum of different HIV-1 variants. The results revealed that semen only had a minimal effect on the antibodies' ability to neutralize the virus. This is promising because it suggests that these antibodies could still be effective in microbicides, even in the presence of semen. Understanding this interaction is crucial for developing better strategies to prevent HIV-1 transmission. By incorporating the knowledge gained from this study, scientists can now focus on creating microbicides that consider the impact of semen, bringing us closer to more effective prevention methods.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies
    Misra, Milind
    Jeffy, Jeffy
    Liao, Charis
    Pickthorn, Stephanie
    Wagh, Kshitij
    Herschhorn, Alon
    BIOINFORMATICS, 2024, 40 (03)
  • [32] Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities
    Liu, Yubin
    Cao, Wei
    Sun, Ming
    Li, Taisheng
    EMERGING MICROBES & INFECTIONS, 2020, 9 (01) : 194 - 206
  • [33] Broadly neutralizing antibodies against HIV-1: Templates for a vaccine
    van Gils, Marit J.
    Sanders, Rogier W.
    VIROLOGY, 2013, 435 (01) : 46 - 56
  • [34] Broadly neutralizing antibodies against HIV-1 and concepts for application
    Gruell, Henning
    Schommers, Philipp
    CURRENT OPINION IN VIROLOGY, 2022, 54
  • [35] Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    Hua-Xin Liao
    Rebecca Lynch
    Tongqing Zhou
    Feng Gao
    S. Munir Alam
    Scott D. Boyd
    Andrew Z. Fire
    Krishna M. Roskin
    Chaim A. Schramm
    Zhenhai Zhang
    Jiang Zhu
    Lawrence Shapiro
    James C. Mullikin
    S. Gnanakaran
    Peter Hraber
    Kevin Wiehe
    Garnett Kelsoe
    Guang Yang
    Shi-Mao Xia
    David C. Montefiori
    Robert Parks
    Krissey E. Lloyd
    Richard M. Scearce
    Kelly A. Soderberg
    Myron Cohen
    Gift Kamanga
    Mark K. Louder
    Lillian M. Tran
    Yue Chen
    Fangping Cai
    Sheri Chen
    Stephanie Moquin
    Xiulian Du
    M. Gordon Joyce
    Sanjay Srivatsan
    Baoshan Zhang
    Anqi Zheng
    George M. Shaw
    Beatrice H. Hahn
    Thomas B. Kepler
    Bette T. M. Korber
    Peter D. Kwong
    John R. Mascola
    Barton F. Haynes
    Nature, 2013, 496 : 469 - 476
  • [36] Activity of Broadly Neutralizing Antibodies Against Recently Transmitted Subtype B HIV-1 Variants from Early and Late in the Endemic
    Euler, Z.
    Bunnik, E. M.
    Burger, J. A.
    Boeser-Nunnink, B. D.
    Grijsen, M. L.
    Prins, J. M.
    Schuitemaker, H.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2011, 27 (10) : A41 - A41
  • [37] Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus
    Liao, Hua-Xin
    Lynch, Rebecca
    Zhou, Tongqing
    Gao, Feng
    Alam, S. Munir
    Boyd, Scott D.
    Fire, Andrew Z.
    Roskin, Krishna M.
    Schramm, Chaim A.
    Zhang, Zhenhai
    Zhu, Jiang
    Shapiro, Lawrence
    Mullikin, James C.
    Gnanakaran, S.
    Hraber, Peter
    Wiehe, Kevin
    Kelsoe, Garnett
    Yang, Guang
    Xia, Shi-Mao
    Montefiori, David C.
    Parks, Robert
    Lloyd, Krissey E.
    Scearce, Richard M.
    Soderberg, Kelly A.
    Cohen, Myron
    Kamanga, Gift
    Louder, Mark K.
    Tran, Lillian M.
    Chen, Yue
    Cai, Fangping
    Chen, Sheri
    Moquin, Stephanie
    Du, Xiulian
    Joyce, M. Gordon
    Srivatsan, Sanjay
    Zhang, Baoshan
    Zheng, Anqi
    Shaw, George M.
    Hahn, Beatrice H.
    Kepler, Thomas B.
    Korber, Bette T. M.
    Kwong, Peter D.
    Mascola, John R.
    Haynes, Barton F.
    NATURE, 2013, 496 (7446) : 469 - +
  • [38] Multivariant HIV-1 infection in infants with broadly neutralizing plasma antibodies: Implication for polyvalent vaccines
    Mishra, N.
    Sharma, S.
    Dobhal, A.
    Makhdoomi, M.
    Kumar, S.
    Singh, R.
    Das, B.
    Lodha, R.
    Kabra, S.
    Luthra, K.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 5 - 5
  • [39] Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies
    Cheeseman, Hannah M.
    Olejniczak, Natalia J.
    Rogers, Paul M.
    Evans, Abbey B.
    King, Deborah F. L.
    Ziprin, Paul
    Liao, Hua-Xin
    Haynes, Barton F.
    Shattock, Robin J.
    JOURNAL OF VIROLOGY, 2017, 91 (01)
  • [40] Founder Env-specific IgM B cell responses during acute HIV-1 infection associate with the development of broadly neutralizing antibodies
    Townsley, S.
    Donofrio, G.
    Jian, N.
    Leggat, D.
    Dussupt, V.
    Mendez-Rivera, L.
    Eller, L. A.
    Slike, B.
    Ehrenberg, P.
    Geretz, A.
    Doria-Rose, N.
    Polonis, V.
    Mascola, J.
    Rolland, M.
    Tovanabutra, S.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24